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Abstract
Purpose The aim of this investigation was to quantitatively
compare the novel positron emission tomography (PET)
hypoxia marker 2-(2-nitroimidazol-1-yl)-N-(3[18F],
3,3-trifluoropropyl)acetamide ([18F]EF3) with the reference
hypoxia tracer [18F]fluoromisonidazole ([18F]FMISO).
Methods [18F]EF3 or [18F]FMISO was injected every
2 days into two separate groups of rats bearing syngeneic
rhabdomyosarcoma tumours. In vivo PET analysis was
done by drawing regions of interest on the images of
selected tissues. The resulting activity data were quantified
by the percentage of injected radioactivity per gram tissue
(%ID/g) and tumour to blood (T/B) ratio. The spatial
distribution of radioactivity was defined by autoradiogra-
phy on frozen tumour sections.
Results The blood clearance of [18F]EF3 was faster than
that of [18F]FMISO. The clearance of both tracers was
slower in tumour tissue compared with other tissues. This
results in increasing T/B ratios as a function of time post
tracer injection (p.i.). The maximal [18F]EF3 tumour
uptake, compared to the maximum [18F]FMISO uptake,
was significantly lower at 2 h p.i. but reached similar levels
at 4 h p.i. The tumour uptake for both tracers was
independent of the tumour volume for all investigated time
points. Both tracers showed heterogeneous intra-tumoural
distribution.
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Conclusions [18F]EF3 tumour uptake reached similar levels
at 4 h p.i. compared with tumour retention observed after
injection of [18F]FMISO at 2 h p.i. Although [18F]EF3 is a
promising non-invasive tracer, it is not superior over [18F]
FMISO for the visualisation of tumour hypoxia. No
significant differences between [18F]EF3 and [18F]FMISO
were observed with regard to the intra-tumoural distribution
and the extra-tumoural tissue retention.
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Introduction
Oxygen deficiency (hypoxia) is heterogeneously spread in
regions of solid tumours as a result of rapid cellular
expansion and/or insufficient tumour angiogenesis [1, 2].
Hypoxia has been related to increased malignant progres-
sion and metastatic potential of primary carcinomas as well
as to resistance to cancer therapies [3, 4]. Strategies to
counteract the negative effect of intra-tumoural hypoxia are
being evaluated [5], but not all patients show benefits from
such selective treatments. To facilitate treatment guidance in
individual patients, a variety of methods have been
proposed to measure oxygenation levels in tumoural tissues.
During the last 20 years, a lot of research has been
devoted to non-invasive imaging techniques for the
detection of hypoxia in solid tumours. One such technique
involves positron emission tomography (PET) using radio-
labelled nitroimidazoles. In hypoxic environments, these
compounds are subject of a reductive metabolism, which
causes the formation of reactive intermediates (nitrose and
hydroxylamine) that become covalently bound to macro-
molecular cellular components [6]. Based on this principle,
their selective binding to hypoxic cells has already been
demonstrated in vitro as well as in vivo [7–10].
[18F]Fluoromisonidazole ([18F]FMISO) was the first
radiolabelled 2-nitroimidazole derivative proposed for
hypoxia imaging with PET [11]. This tracer has been
evaluated extensively for the detection of tumour hypoxia
both pre-clinically, using different animal models [12–15],
and clinically, for different cancer types [16–19]. Other 18F-
labelled nitroimidazoles, such as [18F]FETNIM [20, 21]
and [18F]FAZA [22, 23], have been synthesized and
validated as hypoxia markers. However, being more
hydrophilic compounds, the latter PET tracers’ diffusion
into tumoural tissues might be limited [24]. Therefore, a
new class of more lipophilic, fluorinated etanidazole
compounds (e.g. EF3 and EF5) is of potential interest.
Preliminary animal experiments involving these fluorinated
derivatives indicated more homogeneous distribution in
normal tissues together with tracer clearance through the
kidneys and tracer accumulation in hypoxic tumours [25,
26]. Recently, Josse et al. successfully radiolabeled 2-
(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)acetamide
(EF3) using 18F for PET-based hypoxia evaluation [27].
Based on ex vivo pharmacokinetics and biodistribution data,
Mahy et al. demonstrated that [18F]EF3 could be a good
alternative for [18F]FMISO for the detection of tumour
hypoxia [28].
The aim of the present study was to quantitatively
compare the in vivo hypoxia-dependent uptake of [18F]EF3
and [18F]FMISO in experimental rat tumours by non-
invasive investigation with PET. The experiments also
involved the evaluation of the in vivo pharmacokinetics of
both tracers and their biodistribution in normal tissues.
Materials and methods
Animal and tumour model
Male adultWAG/Rij rats with an average bodyweight of 315 g
were used. Each rat was implanted subcutaneously under
sodium pentobarbital anaesthesia (Nembutal 0.1 ml 100 g−1
body weight; Sanofi, Belgium) with syngeneic rhabdo-
myosarcomas (1-mm3 R1 tumours; [29]) in the lateral
thorax or in the abdominal flank. Tumours were measured
every day during the experiment using a Vernier caliper in
three orthogonal tumour diameters A, B and C, each
corrected for the thickness of the skin. Volumes were
calculated using the formula A×B×C×π/6, since the
tumours grew elliptically. PET measurements were per-
formed within a 2-week follow-up. Procedures were
performed according to the guidelines defined in the
“Principles of laboratory animal care” (NIH publication
no. 86-23, revised 1985). All animals were maintained in a
facility which was approved by the Belgian Ministry of
Agriculture in accordance to current regulations and
standards. Animals were given food and water ad libitum
for the duration of the experiments. The experimental
design was approved by the Animal Ethics Committee of
the Katholieke Universiteit Leuven, Leuven (FMISO
experiment) and of the Université Catholique de Louvain,
Louvain-la-Neuve (EF3 experiment).
Synthesis of the hypoxia markers
The 18F-labelled 2-nitroimidazole derivative 2-(2-nitroimi-
dazol-1-yl)-N-(3,3,3-trifluoropropyl)acetamide ([18F]EF3)
(Fig. 1a) was synthesised as previously described [27].
Briefly, the radiolabelled perfluorinated aminodithioester
precursor group was de-protected and coupled to 2-nitro-
imidazole acetic acid to generate [18F]EF3, which was
isolated by reverse phase semi-preparative high-perfor-
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mance liquid chromatography (HPLC). The HPLC-isolated
[18F]EF3 fractions demonstrated a radiochemical purity
higher than 95%. Specific radioactivity was typically in the
range of 150 GBq/mmol reflecting the difficulty and yield
of the [18F]EF3 synthesis.
[18F]FMISO (Fig. 1b) was produced by the nucleophilic
substitution of 1-(2′-nitro-1′-imidazolyl)-2-O-tetrahydropyr-
anyl-3-O-toluenesulfonylpropandiole with [18F]fluoride fol-
lowed by acidic hydrolysis of the protecting group, as
described by Lim and Berridge [30]. Radiochemical purity
was always higher than 95%; specific radioactivity was
higher than 37,000 GBq/mmol.
Experimental design
Two different sets of tumour-bearing rats with similar
starting volumes were injected with either [18F]EF3 or
[18F]FMISO at different imaging centres. Injection of the
tracer occurred at a 2-day interval to assure complete
clearance between successive studies. Prior to and during
PET acquisition, the animals were anaesthetised with
sodium pentobarbital at a dose of 0.1 ml 100 g−1 body
weight, injected intraperitoneally. The radiolabelled tracer
was administrated via an intravenous catheter (Venoflux
0.4 mm G.27; Vygon, France) inserted into a lateral tail
vein, flushed with diluted heparin saline solution. The
bladder of the animal was emptied by gentle pressure at the
lower abdominal area before each PET acquisition and
the rats were placed in a custom-built, polystyrene foam
placed in the opening of the camera. During PET image
acquisition, anaesthesia was maintained using individual
rat-adapted intraperitoneal injections (10–30% of the initial
dose) of the anaesthetic, as needed. Following the PET
acquisitions, a blood sample from each animal was
collected by retro-orbital puncture and [18F]EF3 radioac-
tivity concentration in the blood samples was measured
using a gamma counter (1480 Wallac Wizard 3″ Automatic
Gamma Counter, PerkinElmer, USA). At defined time
points, randomly selected rats were euthanised by an
overdose of sodium pentobarbital injected into the heart
and tumours were removed immediately for histopatholog-
ical examination.
PET imaging
PET images with [18F]FMISO were obtained at the
Department of Nuclear Medicine KU Leuven as previously
described [13]. PET imaging with [18F]EF3 was performed
at the UCL Centre for Molecular Imaging and Experimental
Radiotherapy, using an ECAT HR scanner (Siemens/CTI
Knoxville) with an axial field of view (AFOV) of 15 cm
and a reconstructed spatial resolution of 8 mm full-width at
half-maximum at the centre of the FOV. Phantom measure-
ments were performed on both imaging devices to compute
calibration factors and thus enabling comparison between
images obtained with both cameras.
The PET sequence started with a 15-min transmission
scan using external rods of 68Ge to allow subsequent
attenuation correction of the emission images. Simulta-
neously with tracer injection into a lateral tail vein (12.22±
1.63 MBq [18F]FMISO or 19.69±2.22 MBq [18F]EF3), a
dynamic emission scanning (26 frames) to obtain heart
outflow clearance data was started for 60 min, according to
the following protocol: 8×15 s, 4×30 s, 2×1 min, 2×
2 min, 10×5 min. Two hours post injection (p.i.), a second
dynamic emission scan for 20 min (4×5 min) following
repositioning and a 15-min transmission scan were per-
formed as previously described [13]. To allow extensive
comparison with [18F]FMISO, the same sequence (trans-
mission followed by 20-min dynamic emission) was
repeated twice (3 and 4 h p.i.) on the [18F]EF3-injected
animals. All images were reconstructed iteratively (2D-
OSEM) using attenuation factors obtained from the trans-
mission scans. The images were also corrected for scatter,
randoms, deadtime, frame duration and decay to the start of
each emission scan. The activity concentrations, obtained in
selected tissues from regions of interest (ROI) drawn on the
images, were subsequently corrected for decay towards the
time of injection.
PET image analysis
Blood pool activity data were obtained by drawing a
volume of interest (VOI) with an average diameter of 9 mm
on the outflow area of the heart, which was defined with the
aid of the early perfusion images. To validate these data,
Fig. 1 Chemical structure of the 2-nitroimidazole hypoxia markers
(a) trifluoropropyl acetamide derivative (EF3) and (b) fluoromisoni-
dazole (FMISO)
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they were compared to the results obtained from the blood
samples quantified using ex vivo counting in a gamma
counter which was cross-calibrated versus the PET scanner.
Blood clearance curves for both tracers were then created
by plotting the activity values within each VOI in all single
time frames of the dynamic acquisition (expressed as
percent of injected dose per gram tissue) against time.
Normal tissue evaluation was done using VOI analysis
(diameter of 9 mm) on the lung, muscle (as described in
[8]) and head and neck (H&N) area (as described in [31]).
Tracer uptake in tumours was evaluated by VOI analysis on
the summed frames at 2, 3 and 4 h p.i. VOIs were defined
by drawing isocontours on all slices where visible tumour
uptake was present. All activity data were corrected for 18F
decay and quantified by calculation of the percentage of
injected radioactivity per gram tissue (%ID/g). The mean
and maximal activities for [18F]EF3 and [18F]FMISO were
obtained from the selected tissue VOI and divided by the
mean activity of a heart outflow VOI to calculate tissue to
blood (T/B) ratios.
Histology
Excised tumours were fixed in neutral buffered formalin (1–
4%), embedded in paraffin and cut into 5-μm-thick slices
using a Leica-2045 microtome (Germany). Slices were de-
paraffinised with toluene and rehydrated by treatment with a
series of alcohol and water mixtures and finally with water.
Tissue sections were stained using Mayer’s haematoxylin
(Klinipath b.v. Belgium) for 5 min. After incubation in tap
water (10 min), the sections were counterstained with eosin
(Klinipath b.v. Belgium) for 3 min, dehydrated and mounted.
Sections were scored by means of moving a ‘10×10’ grid-
incorporated ocular, superimposed on the image, at a total
magnification of ×200. For each tumour, an average of 807±
319 hit-points were evaluated and the necrotic fraction (NF)
was calculated.
Autoradiography
Additional tumour-bearing rats (n=5) were injected with
either [18F]FMISO (84.75±9.36 MBq) or [18F]EF3 (108.25±
8.00 MBq). Upon euthanasia at 2 or 4 h p.i., tumours were
excised, rapidly frozen in 2-methylbutane (cooled to −25°C
with liquid nitrogen) and cut with a Leica-CM-3050
cryotome (Germany) into 7-μm-thick sections. Selected
tumour sections were mounted onto microscope slides, air-
dried and exposed overnight to a high-performance storage
phosphor screen (Packard, Meriden, USA). The spatial
distribution of radioactivity was autoradiographically
recorded with a Phosphor Imager Scanner (Packard
Cyclone TM, Meriden, USA). The resolution of the images
expressed in pixel size was 42×42 μm (600 dpi).
Statistics
All statistical analyses were performed with SPSS 12.0.1
for Windows (SPSS, 2003, Chicago, USA). Graphs were
drawn using Origin 6.0 (Microcal Software, 1999, North-
ampton, USA). Correlation among the variables was
analysed using Spearman rank order correlation and
additionally evaluated by linear regression. An unpaired
Student’s t test and non-parametric Mann–Whitney U test
for small groups were used to determine the statistical
significance of differences between two independent groups
of variables. For all tests, a P<0.05 was considered
significant.
Results
Heart outflow as reference tissue
Comparison (Fig. 2) of the heart outflow data, defined by
VOI–PET analysis on [18F]EF3 images with the blood
activity data quantified ex vivo in a gamma counter, resulted
in a strong, significant correlation (r2=0.924; P<0.001; y=
1.006x+34.792). ROI analysis of the heart outflow area
was performed independently by a second observer. No
significant difference (P=0.986) was seen. Based on these
results, the heart outflow was selected as reference tissue
for the calculation of the T/B ratios.
Fig. 2 Validation of heart ‘outflow’ as reference tissue by compar-
ison, after phantom-based cross-calibration, between [18F] activity
defined by image analysis of the heart and gamma counter analysis of
blood samples. Heart outflow area analysis data represent the mean
±SD of three independent analyses of 20 animals. Heart ‘outflow’
regions were defined on the [18F]EF3 images acquired using the
ECAT HR scanner from the UCL imaging facility
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Blood pharmacokinetics
For analysis of the blood pharmacokinetics, we used the
mono-compartmental hypothesis. Data were better fitted
applying a bi-exponential elimination model (r2=0.614 for
[18F]FMISO and r2=0.787 for [18F]EF3) compared to a
mono-exponential model (r2=0.399 and 0.569 for [18F]
FMISO and [18F]EF3, respectively). The [18F]EF3 initial
and late elimination half-lives (up to 2 h p.i.) were 0.62 min
(0.56–0.70 min) and 51.36 min (42.63–64.56 min), respec-
tively. The pharmacokinetics of [18F]FMISO were slower
with elimination half-lives of 1.19 min (1.03–1.42 min) and
94.59 min (70.44–143.95 min). Linear regression analysis
showed a significant difference in clearance for both tracers
(P<0.001), as witnessed from the interaction between time
and group (Fig. 3). [18F]EF3 elimination half-lives up to 4 h
p.i. were only slightly different: 0.65 min (0.58–0.72 min)
and 59.72 min (49.75–74.65 min).
PET analysis of normal tissues
Comparison between [18F]EF3 and [18F]FMISO normal
tissue uptake, investigated in the H&N area and muscle
(front and hind leg) area on the 2 h p.i. images, did not
reveal statistical differences, except for lung tissue where
the [18F]FMISO T/B ratio was lower than the [18F]EF3 T/B
ratios (P<0.001) (Table 1). No significant differences were
observed between mean and maximum activity data for all
investigated normal tissues (data not shown), confirming
the homogeneous uptake characteristics in these tissues. All
normal tissues exhibited activity levels lower than in the
blood, resulting in T/B ratios below unity. Later time points
(3 and 4 h p.i.) did not demonstrate differences in [18F]EF3
T/B ratios compared with 2 h p.i. (Table 1).
PET analysis of tumour tissues
No significant differences (P=0.285) were found between
the median of the tumour volumes for the animals in the
[18F]EF3 (0.87 cm3) and [18F]FMISO (0.94 cm3) group,
which allows comparison of the results obtained with both
tracers. The decrease in [18F]EF3 activity concentration as a
function of time was fastest in blood and the washout was
lowest in tumour tissue, resulting in increasing T/B ratios
over time. Since tumours are known to be heterogeneous,
we analysed the T/B ratios based both on mean and
maximum tumour concentration. A statistical difference
was observed between the two T/B values, both for [18F]
FMISO and [18F]EF3 (P<0.001). The increase in T/B ratio
over time was faster for tumoural regions which showed the
highest radioactivity concentration (Table 1). The maxi-
mum [18F]EF3 uptake at 2 h p.i. was significantly lower
(P<0.001) compared with the [18F]FMISO activity uptake
at the same time point (Fig. 5a). However, at 4 h p.i.,
maximum [18F]EF3 T/B ratios were not significantly
different anymore compared with the maximum [18F]
FMISO T/B ratios at 2 h p.i. (P=0.088). Comparison of
the mean uptake indicated statistical differences between
both tracers for all investigated time points (P<0.001). The
maximum [18F]FMISO uptake (%ID/g) was independent of
Table 1 Uptake (T/B ratio) of [18F]FMISO and [18F]EF3 at 2 h p.i.
and of [18F]EF3 at 3 and 4 h p.i. in selected normal tissues and
tumours
[18F]FMISO [18F]EF3
2 h p.i. 2 h p.i. 3 h p.i. 4 h p.i.
Tissue/blood
H&N area 0.88±0.02 0.88±0.02 0.90±0.02 0.90±0.02
Muscle front
leg
0.97±0.02 0.89±0.02 0.90±0.02 0.88±0.03
Muscle hind
leg
0.95±0.03 0.92±0.05 0.93±0.03 0.94±0.03
Lung 0.60±0.02 0.80±0.02 0.83±0.03 0.82±0.03
Tumour/blood
All (mean) 3.99±0.18 1.83±0.06 2.25±0.09 2.63±0.11
<1 cm3 3.87±0.28 1.65±0.09 1.95±0.13 2.35±0.17
>1 cm3 4.13±0.22 2.09±0.07 2.67±0.11 3.03±0.12
All (max) 5.46±0.27 2.89±0.11 3.86±0.18 4.84±0.23
<1 cm3 5.11±0.42 2.55±0.15 3.21±0.22 4.26±0.33
>1 cm3 5.86±0.31 3.38±0.14 4.78±0.24 5.66±0.25
Normal tissues: n=12 for [18 F]FMISO and n=20 for [18 F]EF3.
Tumours: n=48 for [18 F]FMISO (<1 cm3 : n=26; >1 cm3 : n=22) and
n=80 for [18 F]EF3 (<1 cm3 : n=44; >1 cm3 : n=36). Data are
presented as the mean±SD
Fig. 3 Time–activity blood clearance curves for [18F]EF3 (squares) and
for [18F]FMISO (triangles) up to 2 h p.i. Data represent the mean±
SD of eight and ten animals injected with [18F]EF3 or [18F]FMISO,
respectively
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the tumour volume for all investigated time points (Fig. 4
and Table 2). [18F]EF3 uptake, however, seemed to better
correlate with the tumour volume. Mean uptake data
showed comparable results (data not shown). We found a
correlation (r2=0.508 and P=0.009) between the NF and
tumour volume with a clear significant separation in NF
between tumours smaller (NF=5.8±1.8%) and larger (NF=
39.1±7.8%) than 1 cm3 (P=0.004; data not shown). When
comparison was made between tracer uptake and tumour
volumes separately for tumours smaller or larger than
1 cm3, similar results were obtained (Table 2) as for the
whole dataset.
Autoradiography
Autoradiographic analysis of the frozen tumour sections
obtained from rats 2 or 4 h post intravenous injection of
respectively [18F]FMISO or [18F]EF3 showed that both
tracers were heterogeneously distributed within tumours
(Fig. 5b). On average, the [18F]FMISO tracer uptake was
higher compared with the [18F]EF3 uptake.
Discussion
Over the last decade, interest into the development of
radiolabelled markers for the non-invasive diagnosis of
tumour hypoxia in solid tumours has increased dramatically.
Based on its high cellular uptake and trapping in hypoxic
cells, [18F]FMISO has been tested for in vivo visualization
of reduced oxygen tension in tumours, both in pre-clinical
[12–15] and clinical [17, 19] settings. [18F]FMISO has also
been indicated to be a valuable tool for therapy response
evaluation [16, 18]. However, the diffusion of [18F]FMISO
into tissues and, in particular, into tumour tissues, which are
known to have abnormal vascularisation, might not be
optimal due to the hydrophilicity of the compound (octanol-
to-buffer partition coefficient of 0.4).
Fig. 4 Maximum [18F]FMISO tracer uptake (%ID/g) at 2 h p.i. (a)
and maximum [18F]EF3 tracer uptake at 2 h p.i. (b), 3 h p.i. (c) and 4 h
p.i. (d) plotted against tumour volume (cm3). Filled squares represent
tumours smaller than 1 cm3 (n=44 for [18F]EF3 and n=26 for [18F]
FMISO) whilst open squares show tumours larger than 1 cm3 (n=36
for [18F]EF3 and n=22 for [18F]FMISO). Note differences in scales on
the Y-axis
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Therefore, a new class of more lipophilic fluorinated
compounds, such as EF3 [25] and EF5 [26] showing an
octanol-to-buffer partition coefficient of 1.12 and 5.7,
respectively, have been developed. Recently, EF3 has been
radiolabelled with 18F ([18F]EF3) [27] and based on ex vivo
pharmacokinetics and biodistribution data, Mahy et al.
demonstrated that [18F]EF3 could be a good candidate for
the detection of tumour hypoxia [28]. The use of [18F]EF3
to detect tumour hypoxia has been further validated by
comparison with the intracellular EF5 uptake as detected by
immunofluorescence [32]. On the other hand, Dubois et al.
validated the non-invasive [18F]FMISO–PET method to
measure tumour hypoxia by comparison with the exoge-
nous hypoxia marker pimonidazole [13]. Further pre-
clinical in vivo evaluation of [18F]EF3 by comparison with
other radiolabelled hypoxia tracers is a very important
issue. The aim of the present study has been to quantita-
tively compare the selectivity of hypoxia-dependent uptake
of both tracers in the same experimental rat tumour model
using in vivo PET.
We evaluated the potential use of the heart ‘outflow’
ROI as “reference tissue” to avoid retro-orbital sampling of
blood, a procedure which may cause radioactive contami-
nation and which may interfere with the quality of life of
the animals particularly when performed repeatedly. More-
over, the heart ‘outflow’ ROI was preferred as reference
Table 2 r2 and P values for the correlation between maximum tracer uptake (%ID/g) at various time points and tumour volumes
All <1 cm3 >1 cm3
r2 value P value r2 value P value r2 value P value
FMISO 2 h p.i. 0.120 0.016 0.120 0.084 0.047 0.331
EF3 2 h p.i. 0.268 <0.001 0.130 0.013 0.221 0.006
3 h p.i. 0.403 <0.001 0.231 <0.001 0.298 <0.001
4 h p.i. 0.315 <0.001 0.228 <0.001 0.219 0.006
Fig. 5 PET images (a) of mice injected with [18F]FMISO (2 h p.i.)
and [18F]EF3 (2 h and 4 h p.i.). Autoradiography images (b) of
tumours injected with [18F]FMISO at 2 h p.i. (1.66 cm3) or with [18F]
EF3 at 4h p.i. (1.60 cm3). From left to right, peripheral to central
images of the tumours are shown. Both PET (0–100) and autoradi-
ography (0–800) images are scaled to the hottest pixel (=highest tracer
uptake) in the image
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rather than muscle, since tracer uptake in muscle tissue
might be sensitive to changes in oxygenation status [20].
Lehtiö et al. also demonstrated a variable [18F]FETNIM
muscle uptake which could be related to a variable muscle
blood flow caused, for example, by patient stress during the
imaging session [33]. Our data demonstrate a strong
correlation between the [18F]EF3 activity obtained by heart
‘outflow’ region with PET and by blood samples analysis
with gamma counting (r2=0.924; P<0.001). This validates
the use of heart ‘outflow’ as reference tissue to analyse
whole-blood [18F] activity non-invasively, an approach
which deserves attention in clinical PET examination.
[18F]EF3 biodistribution in all investigated normal
tissues was fast and homogeneous. Our data agree with
previous biodistribution studies performed in mice using
[18F]EF3 [28] and in rats using [18F]EF5 [34]. A progres-
sive clearance of [18F]EF3 concentration with time was
observed and the uptake in normal tissues was always
lower than in the blood. This results in maintained T/B
ratios below 1 which is favourable for imaging purposes
[22]. When comparing [18F]EF3 and [18F]FMISO normal
tissue uptake, no statistical differences in T/B ratios were
observed, except for lung tissue.
Previous studies confirmed the use of both [18F]FMISO
[13, 15] and [18F]EF3 [32] to detect tumour hypoxia by
comparison with established immunohistochemistry techni-
ques. In the present study, we found that [18F]EF3 tumour
to blood ratios were significantly lower than the
corresponding [18F]FMISO tumour to blood ratios, when
comparison was made at 2 h p.i. However, [18F]EF3
tumour to blood ratios increased with time, resulting in
radioactivity levels at 4 h p.i. comparable with [18F]FMISO
at 2 h p.i. This finding is comparable with the difference in
the rate of tracer binding in hypoxic tumour cells as well as
with the faster [18F]EF3 clearance from blood. Even though
the tumour to blood ratios for [18F]EF3 reached similar
values to [18F]FMISO but at a later time, this is probably
not helpful since image quality will always be poorer at 4 h
p.i. than at 2 h p.i. due to decay. Similar results were
reported by other groups for EF3 [28], but also for the 2-
nitroimidazole analogues EF1 [35] and EF5 [34]. A
possible explanation for the discrepancy between [18F]EF3
and [18F]FMISO tumour uptake could be the use of the
anaesthetic sodium pentobarbital, since this could cause
substantial physiological changes in uptake. However, a
recent study demonstrated that the structurally related
phenobarbital did not affect the tumour to blood ratio (P=
0.27) in C3Hf/kam mice bearing syngeneic FSA II
fibrosarcoma tumours [36]. Another, more plausible expla-
nation would be the use of different PET scanners with
inherent different resolution and sensitivity. However,
phantom measurements were performed on both systems
and correction factors were obtained and included in the
reconstruction of the images. Therefore, we believe that the
demonstrated discrepancy between [18F]EF3 and [18F]
FMISO tumour uptake and the following conclusions are
still valid.
Some studies showed heterogeneity in larger tumours
and a more uniform tracer distribution in smaller tumours
[12, 20]. In a previous study, we showed, however,
heterogeneity of [18F]FMISO uptake both in small and
large rhabdomyosarcoma tumours [13]. The [18F]FMISO-
PET images demonstrated a clear heterogeneous tracer
distribution in the tumours. The [18F]EF3-PET images,
however, indicated a more homogeneous tracer distribu-
tion. To further investigate this phenomenon, we used
autoradiography images with higher resolution to compare
the [18F]EF3 and [18F]FMISO radioactivity uptake in
tumours with similar size. The images demonstrated a
heterogeneous distribution within all tumours for both
tracers. For reasons of heterogeneity, we analysed both the
mean and the maximum activity uptake as done by Sorger
et al. [23]. We observed that the maximum [18F]EF3 T/B
ratios increased faster over time than the mean T/B ratios.
In addition, both mean and maximum 18F-labelled hypoxia
tracer uptake ([18F]EF3 and [18F]FMISO) were indepen-
dent of the tumour volume. Experimental animal studies
[12, 14, 20] as well as clinical studies [17–19, 37] have
demonstrated similar results using [18F]FMISO. However,
in our study, [18F]EF3 uptake seemed to correlate better
with tumour volume compared with [18F]FMISO uptake.
Differences in lipophilicity compared with [18F]FMISO
could not explain this better relationship, since both the
uptake of the more hydrophilic hypoxia marker [18F]
FETNIM [20] or the more lipophilic tracer EF5 [38] has
been shown to be independent of the tumour volume.
Based on histological evaluation of tumour necrosis, we
found a correlation between the tumour volume and NF
with a clear significant separation in NF between tumours
smaller and larger than 1 cm3. Although a statistical
difference was observed between the NF of both groups,
mean and maximum tracer uptake were also independent
of the tumour volume when analysing both groups
separately. Also, in this case, [18F]EF3 uptake demonstrat-
ed a better correlation with tumour volume compared with
[18F]FMISO uptake. The overall trend, however, indicates
the use of maximum activity data, since Stadler et al.
demonstrated that the maximum level of FMISO uptake is
most closely related to the biological changes induced by
the genomic instability associated with hypoxia and may
reflect the severity of hypoxia [39]. In addition, it has been
shown recently that FMISO maximum T/B ratios were
highly predictive in a multivariate analysis [17] and lead to
an enhancement of the reproducibility of the measure-
ments together with a reduced effect of the partial volume
effects [40].
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Conclusion
Using PET in an experimental rat model, we showed that
[18F]EF3 is cleared slightly faster from the blood compared
to the [18F]FMISO reference hypoxia marker. The maximum
[18F]EF3 tumour uptake was significantly lower at 2 h p.i.,
but similar at 4 h p.i. compared with the [18F]FMISO uptake
at 2 h p.i. Additionally, we showed a similarly fast and
uniform distribution of both tracers in normal tissues and the
intra-tumoural distribution was comparable. Finally, maxi-
mum activities should be used since it is shown that tumour
uptake is heterogeneous and independent of the tumour
volume. Based on the overall results, [18F]EF3 appears to be
a potential in vivo tracer for the non-invasive detection and
evaluation of tumour hypoxia, yet without being superior
over [18F]FMISO.
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